Chabiotech Co

Chabiotech Co Current Liabilities

The Current Liabilities of Chabiotech Co (085660.KQ) as of Nov 1, 2026 is 77.56 B KRW. In the previous year, Current Liabilities was 719.93 B KRW — a change of -89.23% (lower).

Current Liabilities

77.56 BKRW

YoY

-89.23%

Last updated:

Current Liabilities of Chabiotech Co is 2025 77.56 B KRW. Current Liabilities of Chabiotech Co was 2024 719.93 B KRW. It decreases by -89.23% lower compared to the previous year.

The Chabiotech Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
227.94 B KRW
Jan 1, 2019
215.37 B KRW
Jan 1, 2020
285.68 B KRW
Jan 1, 2021
187.85 B KRW
Jan 1, 2022
186.39 B KRW
Jan 1, 2023
440.02 B KRW
Jan 1, 2024
719.93 B KRW
Jan 1, 2025
77.56 B KRW
The Chabiotech Co Current Liabilities history
YEARCurrent LiabilitiesYoY
77.56 BKRW-89.23%
719.93 BKRW+63.61%
440.02 BKRW+136.07%
186.39 BKRW-0.77%
187.85 BKRW-34.24%
285.68 BKRW+32.65%
215.37 BKRW-5.51%
227.94 BKRW-0.57%
229.25 BKRW-13.86%
266.13 BKRW+130.38%
115.52 BKRW+4.46%
110.59 BKRW-0.67%
111.34 BKRW-8.62%
121.84 BKRW+4.79%
116.27 BKRW+6.16%
109.53 BKRW+96.34%
55.79 BKRW+352.09%
12.34 BKRW-61.69%
32.21 BKRW+221.83%
10.01 BKRW+21.17%
8.26 BKRW+95.09%
4.23 BKRW+1,089.33%
356.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Chabiotech Co Stock analysis

What does Chabiotech Co do? Cha Biotech Co., Ltd. generates revenue through its bio segment, which provides medical services, develops stem cell and cell therapy products, produces cosmetics and cosmetic raw materials, distributes medical devices, and offers cord blood storage and health care services. The optical segment manufactures optical lenses, optical modules, and other parts for mobile phone cameras. The company serves healthcare providers, medical device distributors, and consumers seeking cosmetic and health services. Its bio segment targets medical and wellness markets, while the optical segment caters to mobile phone manufacturers and component suppliers. The company's products include stem cell therapy solutions, cosmetic raw materials, medical devices, and optical components. It operates through two main segments: bio and optical, with the bio segment focusing on healthcare and wellness services, and the optical segment on manufacturing optical parts for mobile devices. The bio segment's cord blood storage services are a key offering for health-conscious consumers, while the optical segment supplies components to mobile phone camera manufacturers. Cha Biotech's revenue streams come from medical service provision, product development in cell therapy, cosmetic production, medical device distribution, cord blood storage, and optical component manufacturing. The company serves healthcare institutions, cosmetic brands, medical device companies, and mobile phone manufacturers. Its bio segment's health care services and optical segment's mobile phone camera parts are central to its business model. Chabiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chabiotech Co stock

Current Liabilities of Chabiotech Co is 77.56 B KRW in 2025.

Current Liabilities of Chabiotech Co changed from 719.93 B KRW to 77.56 B KRW, representing a -89.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Chabiotech Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Chabiotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Chabiotech Co

All Key Metrics — Chabiotech Co